Access to innovative HIV treatment

Ten years after the signing of ground-breaking licensing agreements between Viiv Healthcare and the Medicines Patent Pool (MPP), as well as Viiv’s direct agreements with Aurobindo Pharma, more than 1 billion packs of generic dolutegravir (DTG) based medicines have reached 24 million people living with HIV in 128 low- and middleincome countries (LMICS), transforming the HIV landscape in those areas of the world. This means that as of 2023, over 90% of people on antiretroviral treatment in these countries are estimated to be on Dtg-based regimens. Thanks to this decade-long partnership, Whorecommended treatment can be developed, produced, and when approved, supplied by 15 generic manufacturers to all low-income, least developed, lower-middle-income and sub-saharan African countries, as well as some upper middleincome countries, addressing the needs of regions with the highest HIV burdens.

Charles Gore, Executive Director, Medicines Patent Pool said, "As we reflect on a decade of collaboration with Viiv Healthcare, we are proud to see that public health-oriented voluntary licensing has had tangible impact in the lives of the people we serve, enabling access to affordable versions of innovative HIV treatments in LMICS.”